Modality
ERT
MOA
TROP-2 ADC
Target
CD20
Pathway
JAK/STAT
CFMeso
Development Pipeline
Preclinical
~Feb 2020
→ ~May 2021
Phase 1
Aug 2021
→ Sep 2029
Phase 1Current
NCT06270666
1,360 pts·Meso
2021-08→2029-09·Terminated
1,360 total pts1 indication
Phase 2
Phase 3
NDA/BLA
Approved
CompletedCurrentUpcoming
Catalysts (1)
2029-09-143.5y awayPh2 Data· Meso
Trial Timeline
Q3Q42022Q2Q3Q42023Q2Q3Q42024Q2Q3Q42025Q2Q3Q42026Q2Q3Q42027Q2Q3Q42028Q2Q3Q42029Q2Q3Q4
P1/2
Termina…
Catalysts
Ph2 Data
2029-09-14 · 3.5y away
Meso
Terminated|StartCompletionToday
Trials (1)
| NCT | Phase | Indication | Status | N | EP |
|---|---|---|---|---|---|
| NCT06270666 | Phase 1/2 | Meso | Terminated | 1360 | DAS28 |
Competitors (10)
| Drug | Company | Phase | Target | MOA |
|---|---|---|---|---|
| JNJ-8637 | Johnson & Johnson | NDA/BLA | CD20 | |
| Lisolucimab | Novartis | Approved | CD20 | |
| ABB-8985 | AbbVie | Phase 2 | CD20 | |
| BAY-6520 | Bayer | Phase 2 | AHR | |
| Bemazumab | Regeneron | Phase 1 | VEGF | |
| ARG-3265 | Argenx | Phase 1/2 | CD20 | |
| GMA-5010 | Genmab | Phase 3 | JAK2 | |
| INC-1582 | Incyte | Phase 1/2 | APOC3 | |
| CRS-6525 | CRISPR Therapeutics | Phase 2 | CD20 | |
| Surarasimod | Xenon Pharma | Phase 2 | SHP2 |